Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AZD3293

- PMLiVE

Cellectis gets FDA nod for ‘off-the-shelf’ CAR-T trial

Investigational New Drug gets go-ahead for trials in patients with two haematological cancers

- PMLiVE

Keytruda filed for first- and second-line bladder cancer

Merck & Co hopes to gain advantage over Opdivo and Tecentriq with first-line setting

- PMLiVE

New outcomes data could unlock Repatha’s potential, says Amgen

Evidence of significant cardiovascular benefit could boost slow sales for projected blockbuster

Biogen Idec building

Biogen completes haemophilia business separation

Spin-out Bioverativ launched to focus exclusively on rare blood disorders

AstraZeneca AZ

2017 set to be a “defining year” for AZ

Potential immuno-oncology blockbuster durvalumab leads the charge for AZ’s new launches

- PMLiVE

Trump talks pricing and manufacturing with pharma

Heads of Celgene, Lilly, Merck & Co, Novartis and trade body PhRMA met at the White House

AstraZeneca AZ

AZ, FibroGen’s anaemia drug on course for first filing this year

Potential first-in-class blockbuster lines up to seek approval in China

- PMLiVE

Lilly pilots enhanced online trial information

Company aims to aid comprehension of the informed consent process

- PMLiVE

AbbVie takes anti-tau drug into phase II for Alzheimer’s

Also testing antibody in rare condition PSP, for which FDA has awarded fast-track designation

- PMLiVE

Real-world evidence

Companies are now recruiting high-level executives to lead well-resourced RWE teams as industry looks to reshape the future

- PMLiVE

AZ drug discovery robot programed for cancer research

Firm says NiCoLA-B is world's most advanced drug discovery robot

Deal Watch December 2016

Allergan, AZ, BMS, Pfizer, Roche and more feature in this month's pharma deals round-up

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links